{"id":7176,"date":"2025-04-26T17:03:26","date_gmt":"2025-04-26T22:03:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=6023"},"modified":"2025-07-13T15:09:30","modified_gmt":"2025-07-13T20:09:30","slug":"nanoscope-participation-at-eyecelerator-and-arvo-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h3 class=\"prntac\" style=\"text-align: center;\"><em>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope&#8217;s optogenetic therapy platforms<\/em><\/h3>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2025\u5e744\u670825\u65e5<\/span><\/span>\u00a0 &#8212; <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308b\u65b0\u898f\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u958b\u767a\u3068\u5546\u696d\u5316\u3092\u901a\u3058\u3066\u3001\u73fe\u5b9f\u4e16\u754c\u3067\u76f2\u76ee\u306e\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u3053\u3068\u306b\u5c3d\u529b\u3059\u308b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u00a0<a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30a2\u30a4\u30bb\u30e9\u30ec\u30fc\u30bf<\/a>\u00a0\u305d\u3057\u3066\u00a0<a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">\u773c\u79d1\u5b66\u7814\u7a76\u30fb\u8996\u899a\u5354\u4f1a\uff08ARVO\uff092025<\/a>\u00a0annual meetings. Nanoscope&#8217;s presentations will be centered around 126-week outcomes following treatment with its\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/technology-2\/\" target=\"_blank\" rel=\"nofollow noopener\">MCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5<\/a>\u00a0\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u6700\u521d\u3067\u552f\u4e00\u306e\u6cbb\u7642\u6cd5\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u306b\u52b9\u679c\u304c\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u3066\u3044\u308b\u3002<\/a>\u00a01\u56de\u9650\u308a\u306e\u6a19\u6e96\u7684\u306a\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u3063\u3066\u6295\u4e0e\u3055\u308c\u308b\u3002.<\/p>\n<p>&#8220;We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy,&#8221; said Dr.\u00a0<span class=\"xn-person\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3<\/span>, co-founder and President of Nanoscope. &#8220;Multi-year benefit is meaningful for patients looking for a one-time, durable treatment option for their irreversible, progressive vision loss due to RP, and it underscores the potential of MCO-010 to redefine the standard of care. It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission.&#8221;<\/p>\n<p>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p>\n<p><b><a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30a2\u30a4\u30bb\u30e9\u30ec\u30fc\u30bf\u00a0<\/a><\/b><br class=\"dnr\" \/><span class=\"xn-chron\">5\u67082\u65e5\uff08\u91d1\uff09<\/span><sup>nd<\/sup>, 2025<br class=\"dnr\" \/>\u30b0\u30e9\u30f3\u30c9\u00a0<span class=\"xn-person\">\u30cf\u30a4\u30a2\u30c3\u30c8\u30fb\u30c7\u30a3\u30a2\u30d0\u30ec\u30fc<\/span>,\u00a0<span class=\"xn-location\">\u30e6\u30bf\u5dde\u30d1\u30fc\u30af\u30b7\u30c6\u30a3<\/span><\/p>\n<p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u53c2\u52a0\uff1a<\/p>\n<ul type=\"disc\">\n<li><b>\u5348\u5f8c12\u664230\u5206\uff5e\u5348\u5f8c1\u664230\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09\u00a0<\/b>\u2013 \u30d1\u30cd\u30eb \u2013 \u79c1\u306f\u89e3\u653e\u3055\u308c\u308b\u3067\u3057\u3087\u3046: \u7dd1\u5185\u969c\u3068\u7db2\u819c\u306b\u5bfe\u3059\u308b\u65b0\u3057\u3044\u85ac\u7269\u9001\u9054\u30a2\u30d7\u30ed\u30fc\u30c1 \u2013 \u535a\u58eb\u3002.\u00a0<span class=\"xn-person\">\u30b5\u30e0\u30fb\u30d0\u30ed\u30f3<\/span>, \u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>\u5348\u5f8c1\u664259\u5206\uff5e\u5348\u5f8c2\u664204\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09\u3001\u30b9\u30c8\u30ed\u30d9\u30ea\u30fc\u30dc\u30fc\u30eb\u30eb\u30fc\u30e0\u00a0<\/b>\u2013 \u30d7\u30ec\u30bc\u30f3\u30c6\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u30b7\u30e7\u30fc\u30b1\u30fc\u30b9\uff1a\u7db2\u819c\uff1a\u907a\u4f1d\u5b50\u6cbb\u7642\u3068\u65b0\u3057\u3044\u4f5c\u7528\u6a5f\u5e8f \u2013 Dr.\u00a0<span class=\"xn-person\">\u30b8\u30e3\u30ec\u30c3\u30c9\u30fb\u30b9\u30c6\u30a3\u30fc\u30d6\u30f3\u30b9<\/span>, \u6226\u7565\u30fb\u4e8b\u696d\u958b\u767a\u62c5\u5f53\u526f\u793e\u9577<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>3:30 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c4\u664215\u5206<\/span><\/b>\u00a0<b>MDT<\/b>\u00a0\u2013 \u30d1\u30cd\u30eb \u2013 \u884c\u304d\u5148\u304c\u308f\u304b\u3089\u306a\u3044\uff1a\u307e\u3059\u307e\u3059\u8907\u96d1\u5316\u3059\u308b\u898f\u5236\u7d4c\u8def\u3092\u30ca\u30d3\u30b2\u30fc\u30c8\u3059\u308b\u305f\u3081\u306e\u30ac\u30a4\u30c0\u30f3\u30b9 \u2013 \u535a\u58eb\u3002.\u00a0<span class=\"xn-person\">\u30b5\u30e0\u30fb\u30d0\u30ed\u30f3<\/span><\/li>\n<\/ul>\n<p><b><a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">ARVO\uff08\u8996\u899a\u30fb\u773c\u79d1\u5b66\u7814\u7a76\u5354\u4f1a\uff09<\/a><br class=\"dnr\" \/><\/b><span class=\"xn-chron\">5\u67084\u65e5\uff08\u65e5\uff09<\/span><sup>\u756a\u76ee<\/sup>\u00a0\u306b\u00a0<span class=\"xn-chron\">5\u67088\u65e5\uff08\u6728\uff09<\/span><sup>\u756a\u76ee<\/sup>, 2025<br class=\"dnr\" \/>\u30bd\u30eb\u30c8\u30d1\u30ec\u30b9\u30b3\u30f3\u30d9\u30f3\u30b7\u30e7\u30f3\u30bb\u30f3\u30bf\u30fc,\u00a0<span class=\"xn-location\">\u30e6\u30bf\u5dde\u30bd\u30eb\u30c8\u30ec\u30a4\u30af\u30b7\u30c6\u30a3<\/span><\/p>\n<p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\uff1a<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">5\u67084\u65e5\uff08\u65e5\uff09<\/span><sup>\u756a\u76ee<\/sup>, 1:30 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c1\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0G\u00a0<\/b>- MS\u3002.\u00a0<span class=\"xn-person\">\u30eb\u30bb\u30ed\u30fb\u30ac\u30eb\u30b7\u30a2<\/span>\u00a0presenting \u2013 &#8220;Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in NHP model of geographic atrophy&#8221;<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">5\u67086\u65e5\uff08\u706b\uff09<\/span><sup>\u756a\u76ee<\/sup>, 9:15 \u2013\u00a0<span class=\"xn-chron\">\u5348\u524d9\u664230\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0B\u00a0<\/b>\u2013 Dr. SriniVas Sadda presenting \u2013 &#8220;126-Week Visual Acuity Outcomes Following Mutation-Agnostic Optogenetic Therapy, MCO-010, for Retinitis Pigmentosa (RP)&#8221;<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">5\u67088\u65e5\uff08\u6728\uff09<\/span><sup>\u756a\u76ee<\/sup>, 2:45 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c3\u6642\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0F\u00a0<\/b>\u2013 \u535a\u58eb.\u00a0<span class=\"xn-person\">\u30ca\u30b8\u30fb\u30b7\u30e3\u30ea\u30d5<\/span>\u00a0presenting \u2013 &#8220;Safety and Efficacy of an Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin Plasmids in African Green Monkey Retinae&#8221;<\/li>\n<\/ul>\n<p>ARVO\u4f1a\u8b70\u306e\u671f\u9593\u4e2d\u3001Nanoscope\u306e\u30c1\u30fc\u30e0\u30e1\u30f3\u30d0\u30fc\u306f\u30d6\u30fc\u30b91337\u306b\u3066\u5bfe\u5fdc\u3044\u305f\u3057\u307e\u3059\u3002.<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u73fe\u5728\u6cbb\u7642\u6cd5\u304c\u306a\u3044\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u5909\u7570\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u30aa\u30d7\u30c8\u30b8\u30a7\u30cd\u30c6\u30a3\u30c3\u30af\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308bRESTORE\u30d5\u30a7\u30fc\u30ba2b\u591a\u65bd\u8a2d\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u306e\u826f\u597d\u306a\u8a66\u9a13\u7d42\u4e86\u7d50\u679c\u3092\u53d7\u3051\u3066\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3001\u540c\u793e\u306f\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">RP\u6cbb\u7642\u85acMCO-010\u306eBLA\u7533\u8acb<\/a>\u00a0\u540c\u793e\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>, 2025\u5e74\u306b\u3082\u3001MCO-010\u306f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u7db2\u819c\u840e\u7e2e\u75c7\uff08GA\uff09\u5411\u3051\u306eIND\u7533\u8acb\u6e96\u5099\u304c\u6574\u3063\u305f\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054\u578bMCO-020\u3001\u304a\u3088\u3073\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\u5411\u3051\u306eAAV\u88fd\u5264\uff08IND\u7533\u8acb\u306b\u5411\u3051\u305f\u7814\u7a76\u4e2d\uff09\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope&#8217;s optogenetic therapy platforms DALLAS,\u00a0April 25, 2025\u00a0 &#8212; Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the\u00a0Eyecelerator\u00a0and\u00a0The Association for Research and Vision in Ophthalmology (ARVO) 2025\u00a0annual meetings. Nanoscope&#8217;s presentations will be centered around 126-week outcomes following treatment with its\u00a0MCO-010 optogenetic therapy\u00a0for retinitis pigmentosa (RP), the first and only therapy\u00a0shown to restore vision in advanced RP patients\u00a0via a one-time, standard intravitreal injection. &#8220;We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7179,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-26T22:03:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-04-26T22:03:26+00:00","article_modified_time":"2025-07-13T20:09:30+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"wordCount":555,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=7176"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176\/revisions"}],"predecessor-version":[{"id":7213,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176\/revisions\/7213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/7179"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=7176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=7176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=7176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}